The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index; 1 of the 10 sources its claims cite were checked for support.
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Open accessAbstract
Background: A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM). Methods: We did an electronic search up to June 30, 2021, for eligible trials. We did a meta-analysis of available trial data using a random-effects model to calculate overall hazard ratios (HRs) and 95% CI (confidence intervals). We included data from 8 CVOTs and 60,080 patients (72.4% with established cardiovascular disease). Results: GLP-1RA reduced major cardiovascular events (MACE) by 14% (HR = 0.86, 95% CI 0.79–0.94, P = 0.006) with a non-significant heterogeneity between subgroups of patients with and without cardiovascular disease (P = 0.127). GLP-1RA also reduced the risk of cardiovascular death by 13% (P = 0.016), nonfatal stroke by 16% (P = 0.007), hospitalization for heart failure by 10% (P = 0.023), all-cause mortality by 12% (P = 0.012), and the broad composite kidney outcome by 17% (P = 0.012), which was driven by a reduction in macroalbuminuria only (HR = 0.74, 0.67–0.82, P < 0.001). Conclusions: GLP-1RA have moderate benefits on MACE, and also reduce hospitalization for heart failure and all-cause mortality; they also have robust benefits on reducing the incidence of macroalbuminuria.
Overview
CoChat Summary
TL;DR
In an updated random-effects meta-analysis of 8 CVOTs and 60,080 patients with type 2 diabetes, GLP-1 receptor agonists reduced MACE by 14% and improved several cardiorenal outcomes, with the largest relative reduction in new macroalbuminuria. Benefits appeared greater in patients with prior cardiovascular disease (16% MACE reduction) than without (6%), but the subgroup interaction was not statistically significant.
Key findings
- GLP-1RA reduced MACE by 14% overall (HR = 0.86, 95% CI 0.79–0.94, P = 0.006). In 6 CVOTs reporting subgroups, MACE was reduced by 16% in patients with prior CVD (HR = 0.84, 95% CI 0.79–0.90, P < 0.001) and by 6% in those without prior CVD (HR = 0.94, 95% CI 0.83–1.06, P = 0.330), with no significant between-subgroup heterogeneity (P = 0.127).
- GLP-1RA reduced cardiovascular mortality by 13% (HR = 0.87, 95% CI 0.78–0.96, P = 0.016), nonfatal stroke by 16% (HR = 0.84, 95% CI 0.76–0.94, P = 0.007), hospitalization for heart failure by 10% (HR = 0.90, 95% CI 0.83–0.98, P = 0.023), and all-cause mortality by 12% (HR = 0.88, 95% CI 0.80–0.96, P = 0.012). Nonfatal myocardial infarction showed a nonsignificant 9% decrease (HR = 0.91, 95% CI 0.81–1.01, P = 0.078).
- In 6 CVOTs, the broad composite kidney outcome was reduced by 17% (HR = 0.83, 95% CI 0.73–0.94, P < 0.012), driven by a reduction in macroalbuminuria only (HR = 0.74, 95% CI 0.67–0.82, P < 0.001), corresponding to a 26% reduction.
- MACE heterogeneity was I² = 50.0% (P = 0.08); the authors report no major risk of bias in any study.
Methods
- Systematic review and meta-analysis following PRISMA, searching PubMed, EMBASE, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov up to June 30, 2021. Eligible trials compared GLP-1RA with placebo in adults with T2DM and included cardiorenal outcomes; 8 CVOTs and 3 secondary analyses were included, totaling 60,080 patients (72.4% with established CVD; mean age 64.0 ± 1.97 years; 62.8% male; follow-up 1.3–5.4 years).
- Random-effects meta-analysis calculated pooled hazard ratios and 95% CIs using the empirical Bayes/Paule-Mandel method with Hartung-Knapp confidence interval adjustment. Heterogeneity was assessed with Cochran’s Q and I²; publication bias was not assessed because fewer than ten trials were included. Analyses used Stata version 16.0.
Limitations
- The authors state that this is a meta-analysis of aggregate trial data, not patient-level data, which limits subgroup investigation and warrants caution about observed treatment-effect differences between patients with and without pre-existing CVD. They did not explore effects by gender, and note that women are generally underrepresented in CVOTs, potentially reducing statistical power.
- The authors also state that inclusion/exclusion criteria and endpoint definitions differed slightly across trials, especially for renal endpoints, and that head-to-head trials would be needed to demonstrate possible superiority within the GLP-1RA class. Publication bias was not assessed because the number of trials was below ten.
- Evident from the text: the protocol was not registered in any platform, all included trials were industry-sponsored, and the small number of trials led to use of a Hartung-Knapp adjustment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
1 Valid · 0 Not valid · 6 Not checked · 24 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“GLP-1RA reduced major cardiovascular events (MACE) by 14% (HR = 0.86, 95% CI 0.79–0.94, P = 0.006)”
- Also stated in: § Outcomes · plain
“In the overall analysis, the risk of MACE was reduced by 14% (HR = 0.86, 95% CI, 0.79–0.94, P = 0.006) compared with placebo”
- Also stated in: § Conclusions · plain
“GLP1-RA reduce the risk of MACE by 14% in eight CVOTs with 60,080 patients with T2DM over a period ranging from 1.3 to 5.4 years.”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Abstract > Results
plainstates a causen = 60,080 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“compared with placebo, treatment with GLP-1RA was associated with a 16% and 6% lower risk of MACE in patients with or without preexisting CV disease, respectively (Table 2).”
- Also stated in: § Outcomes · plain
“No prior CVD | 6 | 0.94 | 0.83–1.06 | 0.330 | 0.0 | 0.420”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Outcomes
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“compared with placebo, treatment with GLP-1RA was associated with a 16% and 6% lower risk of MACE in patients with or without preexisting CV disease, respectively (Table 2).”
- Also stated in: § Outcomes · plain
“Prior CVD | 6 | 0.84 | 0.79–0.90 | < 0.001 | 6.1 | 0.370”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Outcomes
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with no significant heterogeneity between trials (I2 = 50.0%, P = 0.08)”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Outcomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“hospitalization for heart failure by 10% (P = 0.023)”
- Also stated in: § Outcomes · plain
“The risks of hospitalization for heart failure (HR = 0.90, Fig. 8, Table 2) and of all-cause mortality (HR = 0.88, Table 2) were also significantly reduced.”
- Also stated in: § Outcomes · plain
“Heart failure | 8 | 0.90 | 0.83–0.98 | 0.023 | 0.0 | 0.670”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Outcomes · plain
14 more claims
Create a free account to see all 31 claims and to verify the 9 references still open.
- Probably not a substantial claim. 7
- The quote only partly states this claim. 1
- It may state two separate claims as one. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, subcutaneous semaglutide 0.5 and 1.0 mg once weekly, like other GLP‐1RAs [15], has been shown to reduce major adverse CV events (MACE) in patients with type 2 diabetes and high CV risk [16].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study uses standard‐of‐care preventive measures along with semaglutide 2.4 mg subcutaneous once‐weekly treatment, which has been demonstrated to provide significant and sustained mean weight loss of up to 16% [10, 11, 12, 13, 24, 25], significant CV risk factor improvements, and proven CV benefit in patients with diabetes and prior CV events [16, 26].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to improving glucose levels and weight, subcutaneous glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have produced meaningful reductions in major adverse cardiovascular events (MACE) [3].”
From Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These pharmacological agents exhibit beneficial effects on glycemic regulation, weight management, and cardiovascular outcomes, thereby establishing their essential roles in contemporary diabetes management [3-5].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Data from cardiovascular outcome trials and meta-analyses indicate that GLP-1RAs (glucagon-like peptide 1 receptor agonists) reduce the risk of stroke in individuals with type 2 diabetes.”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [47]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| ELIXA | Lixisenatide | 6068 | 60.3 | 3174 (69.3%) | 6068 (100%) | 1922 (20.3%) | 1407 (23.2%) |”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Search results and study characteristics
Reported 20.3 · recomputed 31.674357
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Outcomes
“with no significant heterogeneity between trials (I2 = 50.0%, P = 0.08)”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Methods > Statistical analysis
“P values of less than 0.10 representing significant heterogeneity.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| ELIXA | Lixisenatide | 6068 | 60.3 | 3174 (69.3%) | 6068 (100%) | 1922 (20.3%) | 1407 (23.2%) |”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Search results and study characteristics
Reported 69.3 · recomputed 52.307185
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“37,117 were male (62.8%)”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Search results and study characteristics
Reported 62.8 · recomputed 61.779294
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Outcomes
“Figure: Fig. 10 Forest plots of meta-analysis of the eight CVOTs with GLP-1RA on incidence of new macroalbuminuria”
§ GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs > Results > Outcomes
“| New macro | 6 | 0.74 | 0.67–0.82 | < 0.001 | 11.0 | 0.370 |”
2 more findings
Create a free account to see every finding of this check.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“Search strategy and study selection This systematic review was based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [9].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“SUSTAIN-6 compared semaglutide to placebo in 3297 patients with T2DM and established CV disease or CV risk factors only [17].”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“REWIND compared dulaglutide to placebo in 9901 patients with T2DM and previous CV events or CV risk factors only [20].”
MethodLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“ELIXA compared lixisenatide to placebo in 6068 patients with T2DM who had suffered a recent acute coronary event [15].”
MethodEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Because the prevalence of CVD in the population with T2DM is around 32% [33], at least one fourth of the average patient with T2DM is possible a candidate for the use of the GLP-1RA, or sodium-glucose transporter-2 inhibitors [34], to improve the MACE outcome.”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 1×
“EXSCEL compared extended release exenatide to placebo in 14,752 patients with T2DM and established CV disease or CV risk factors only [18].”
Method
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Hypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 210
2024 Clinical practice guidelines for Hypertension in adults
Kobalava, Z. D., Konradi, A. O., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Baranova, E. I., Barbarash, O. L., Bobkova, N. V., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6117 · Cited by 211
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
Metadata
- Authors
- Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., & Esposito, K.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- MultiMedica (IT)
- Corresponding author
- Giugliano, Dario
- ORCID
- Venue
- Cardiovascular Diabetology
- Published
- 2021-09-15
- Volume
- 20
- Issue
- 1
- Pages
- 189-189
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC8442438
- OpenAlex
- W3200446817
- Cited by
- 263
- References
- 37
- Citations by year
- 2026: 34 · 2025: 54 · 2024: 66 · 2023: 48 · 2022: 56 · 2021: 5
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, cardiovascular outcome trials, major adverse cardiovascular events, cardiovascular mortality, stroke, heart failure hospitalization, all-cause mortality, renal outcomes, macroalbuminuria, cardiorenal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Cause of Death, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Hypoglycemic Agents, Kidney Diseases, Male, Middle Aged, Risk Factors, Incidence, Treatment Outcome, Risk Assessment, Incretins, Cardio-Renal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. https://app.cochat.ai/papers/10.1186/s12933-021-01366-8
- The paper
- Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., & Esposito, K. (2021). GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01366-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.